These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31059418)

  • 1. Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.
    Wheeler C; Mohle-Boetani J
    Public Health Rep; 2019; 134(1_suppl):71S-79S. PubMed ID: 31059418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM; Lobato MN; Lang SG; Wheeler S; Kendig NE; Bur S
    J Public Health Manag Pract; 2019; 25(2):E1-E6. PubMed ID: 30024493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM; Nog R; Wu Y; Dhand A
    Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
    Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M
    J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
    Pease C; Alvarez G; Mallick R; Patterson M; Finn S; Habis Y; Schwartzman K; Kilabuk E; Mulpuru S; Zwerling A
    BMJ Open; 2021 May; 11(5):e047514. PubMed ID: 33986067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
    Holland DP; Sanders GD; Hamilton CD; Stout JE
    PLoS One; 2011; 6(7):e22276. PubMed ID: 21789248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
    Stennis NL; Burzynski JN; Herbert C; Nilsen D; Macaraig M
    Clin Infect Dis; 2016 Jan; 62(1):53-59. PubMed ID: 26338781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
    Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
    Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
    Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
    Haas MK; Aiona K; Erlandson KM; Belknap RW
    Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
    Huang HL; Lee MR; Lee CH; Cheng MH; Lu PL; Sheu CC; Wang JY; Chong IW; Yang JM
    Clin Microbiol Infect; 2024 Nov; 30(11):1410-1417. PubMed ID: 38996972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.